PT Equilab International was established in November 2002. Through incessant research and innovation, this company is dedicated to be an independent provider of Bioavailability/Bioequivalence studies and clinical trials services in Indonesia.
PT Equilab International is the first Bioavailability/Bioequivalence laboratory in Indonesia that has been accredited with ISO/IEC 17025:2000 by The National Accreditation Body of Indonesia (KAN) in August 2004 as a general requirement for Testing and Calibration Laboratory competency. Since April 2007, PT Equilab International has been accredited with ISO/IEC 17025:2005 by KAN replacing ISO/IEC 17025:2000 with accreditation scope of 40 active compounds (as at Oct 2007) and this number will increase from time by time as we develop and validate new analytical methods to determine the compound content in biological specimen.
Located in Jakarta, Indonesia, our 4-storey laboratory has an integrated clinical and analytical site. Our facilities are managed to meet the regulatory requirements and our analytical team offer the innovative technologies, expertise, flexibility, and rapid assay results. Supported by the continuously improvement in quality assurance we are high commitment to quality and confidentiality to be your reliable partner inBioavailability/Bioequivalence studies.
With never ending achievement, Equilab will strengthen its position as the first choice for local, regional, and international pharmaceutical industry. Equilab offers the largest accredited analytical compound database with accreditation status which is recognized not only in Indonesia but also in Asia Pacific and Europe. Equilab experiences and expertise in conducting Bioavailability/Bioequivalence study ensure on time, reliable, and accurate result.
For further information you can contact us by email email@example.com